News|Articles|June 3, 2011

Pharmaceutical Technology Europe

  • Pharmaceutical Technology Europe-06-01-2011
  • Volume 23
  • Issue 6

Optimising High-Potency Manufacture

Effective containment in API and drug-product manufacturing encompasses a variety of process, equipment, and operational issues.

High-containment manufacturing, whether for an active pharmaceutical ingredient or finished drug product, requires specialized approaches in facility design, equipment selection, and manufacturing processes to achieve the desired levels of containment and minimize operator exposure. As with pharmaceutical manufacturing overall, science- and risk-based approaches to reach those goals serve as a crucial framework for optimizing high-potency manufacturing as well for specific elements in the process.

This article was also published in our US sister publication Pharmaceutical Technology and can be read here.

Articles in this issue

over 14 years ago

The EMA And EU Expansion

over 14 years ago

Table Testing Techniques

over 14 years ago

Celebration And Cinema

over 14 years ago

News

over 14 years ago

The Single-Use Technology World Tour

over 14 years ago

New Annex 11: Enabling Innovation

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.